Aurinia Pharmaceuticals Inc (AUPH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.59 is considered Undervalued compared with the five-year average of 3.90. The fair price of Aurinia Pharmaceuticals Inc (AUPH) is between 31.28 to 53.51 according to relative valuation method. Compared to the current price of 14.21 USD , Aurinia Pharmaceuticals Inc By Undervalued By 54.57%.

Relative Value

Fair Zone

31.28-53.51

Current Price：14.21

54.57%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Aurinia Pharmaceuticals Inc (AUPH) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Aurinia Pharmaceuticals Inc (AUPH) has a current Price-to-Book (P/B) ratio of 5.53. Compared to its 3-year average P/B ratio of 3.30, the current P/B ratio is approximately 67.48% higher. Relative to its 5-year average P/B ratio of 3.87, the current P/B ratio is about 42.96% higher. Aurinia Pharmaceuticals Inc (AUPH) has a Forward Free Cash Flow (FCF) yield of approximately 5.91%. Compared to its 3-year average FCF yield of 0.32%, the current FCF yield is approximately 1761.91% lower. Relative to its 5-year average FCF yield of -3.36%, the current FCF yield is about -275.76% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AUPH competitors is 55.11, providing a benchmark for relative valuation. Aurinia Pharmaceuticals Inc Corp (AUPH.O) exhibits a P/S ratio of 6.59, which is -88.03% above the industry average. Given its robust revenue growth of 28.81%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AUPH increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AUPH in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AUPH currently overvalued or undervalued?

Aurinia Pharmaceuticals Inc (AUPH) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.59 is considered Undervalued compared with the five-year average of 3.90. The fair price of Aurinia Pharmaceuticals Inc (AUPH) is between 31.28 to 53.51 according to relative valuation method. Compared to the current price of 14.21 USD, Aurinia Pharmaceuticals Inc is Undervalued By 54.57%.

What is Aurinia Pharmaceuticals Inc (AUPH) fair value?

AUPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Aurinia Pharmaceuticals Inc (AUPH) is between 31.28 to 53.51 according to relative valuation method.

How does AUPH's valuation metrics compare to the industry average?

The average P/S ratio for AUPH's competitors is 55.11, providing a benchmark for relative valuation. Aurinia Pharmaceuticals Inc Corp (AUPH) exhibits a P/S ratio of 6.59, which is -88.03% above the industry average. Given its robust revenue growth of 28.81%, this premium appears sustainable.

What is the current P/B ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Mar 03 2026?

As of Mar 03 2026, Aurinia Pharmaceuticals Inc (AUPH) has a P/B ratio of 5.53. This indicates that the market values AUPH at 5.53 times its book value.

What is the current FCF Yield for Aurinia Pharmaceuticals Inc (AUPH) as of Mar 03 2026?

As of Mar 03 2026, Aurinia Pharmaceuticals Inc (AUPH) has a FCF Yield of 5.91%. This means that for every dollar of Aurinia Pharmaceuticals Inc's market capitalization, the company generates 5.91 cents in free cash flow.

What is the current Forward P/E ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Mar 03 2026?

As of Mar 03 2026, Aurinia Pharmaceuticals Inc (AUPH) has a Forward P/E ratio of 18.95. This means the market is willing to pay $18.95 for every dollar of Aurinia Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Mar 03 2026?

As of Mar 03 2026, Aurinia Pharmaceuticals Inc (AUPH) has a Forward P/S ratio of 6.59. This means the market is valuing AUPH at $6.59 for every dollar of expected revenue over the next 12 months.

AUPH Valuation